Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $24.15M (cash outflow) fell 53.7% year over year, behind the -26.3% change in trailing-twelve-month net income. Sequentially, it fell 82.8% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.

Context

  • Net income amounted to 762355.6% of revenue in FY2025, up 200070.3 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$115.38M (-58.0%) for the fiscal year ending Dec 2026, a slowdown from the -20.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$24.15M-82.8% QoQ
Last fiscal yearDec 2025
-$274.45M-20.0% YoY
LTMMar 2026
-$246.41M-26.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-53.7%+8.8%+62.5 pp
1 year-20.0%-58.0%-38.0 pp
3-year CAGR+14.4%-29.1%-43.5 pp
5-year CAGR-29.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(274.45M) USD
Year-over-year change
+20.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.3% is the 7th highest of 10, against a peer median of +13.8%.
  • Net income amounts to 794858.1% of revenue for LYEL, versus a peer median of 1968.6%.
LYEL Competitors
Net Income for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$246.41M USD-26.3%+14.4%794858.1%
CABACabaletta Bio, Inc.LTM Mar 2026$175.43M USD+38.4%+46.9%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M USD-31.1%-16.9%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$166.01M USD+74.3%+67.3%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$156.4M USD+7.6%+77.4%—
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
EDITEditas Medicine, Inc.LTM Mar 2026$108.95M USD-56.6%-10.1%281.6%
ACIUAC Immune S.A.LTM Dec 2025CHF 70.34M CHF+38.1%-1.7%1968.6%
GNLXGenelux CorporationLTM Mar 2026$33.58M USD+13.8%+83.4%419762.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$27.37M USD-52.6%-18.3%—
AMRNAmarin Corporation plcLTM Mar 2026$5.23M USD+106.0%-28.4%2.4%
Peer median (excluding LYEL) —+13.8%+9.5%1968.6%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Depreciation & Amortization13.62M16.47M20.25M19.63M11.54M
Deferred Income Tax39.51M0000
Stock-Based Compensation62.2M047.08M33.14M41.83M
Change in Working Capital4.02M(82.02M)3.42M(3.12M)(9.89M)
Accounts Receivables00000
Inventory00000
Accounts Payables91K667K1.46M(3.23M)(2.34M)
Other Working Capital3.92M(82.68M)1.96M114K(7.56M)
Other Non-Cash Items4.62M79.11M183K130.95M80.95M
Operating Cash Flow(126.25M)(169.56M)(163.69M)(162.39M)(150.02M)
Capital Expenditures(65.5M)(24.28M)(2.69M)(464K)(780K)
Acquisitions (Net)673.47M00(31.35M)(41.2M)
Purchases of Investments(673.47M)(406.32M)(476.88M)(394.71M)(259.71M)
Sales of Investments617.4M419.05M663.61M548.94M374.68M
Other Investing Activities(673.47M)000(18.9M)
Investing Cash Flow(121.57M)(11.54M)184.05M122.42M54.1M
Debt Repayment00000
Common Stock Issued391.8M11.1M2.2M1.4M50.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.44M(461K)(457K)(76K)(1K)
Financing Cash Flow401.24M10.64M1.74M1.33M50.41M
Effect of Forex Changes0186K(4K)00
Net Change in Cash153.42M(170.27M)22.09M(38.64M)(45.52M)
Free Cash Flow(191.75M)(193.83M)(166.38M)(162.86M)(150.8M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.